Home / Inspections / 1117454

FDA Inspection 1117454 — Novocol Pharmaceutical of Canada, Inc.

Novocol Pharmaceutical of Canada, Inc. — FEI 3002807757

The FDA completed an inspection of Novocol Pharmaceutical of Canada, Inc. on January 30, 2020 in Cambridge. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
January 30, 2020
Fiscal Year
2020
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Cambridge (Canada)

Additional Details

Postmarket Adverse Drug Experience (PADE)

Facility

Other inspections at this facility

  • 1243223 (VAI Fri May 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1098218 (NAI Fri Jun 21 2019 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1093310 (VAI Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1019963 (VAI Wed Jul 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1012538 (VAI Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time))

FDA data resources